NURO - ヌロメトリックス （NeuroMetrix Inc.） ヌロメトリックスNUROのチャート
NUROの企業情報
| symbol | NURO |
|---|---|
| 会社名 | NeuroMetrix Inc （ヌロメトリックス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical/Dental Instruments |
| 業種 | 医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care） |
| 概要 | 事業概要 ニューロメトリックス（NeuroMetrix Inc.）は糖尿病の神経学的合併症の診断と治療に従事する医療機器会社。同社は医療機器の開発を通じて、これらのアンメットニーズに対応するための位置にある。同社は米国で糖尿病性神経障害のための製品の商業的採用を推進する等、糖尿病性神経障害の市場での目標を推進するつもりである。同社は医療機器に一人の患者用バイオセンサーや電極を加える一般的な構造を含む神経診断（neurodiagnostic）システムを開発・販売する。「NC-stat DPNCheck」は電子ハンドヘルドデバイスと一人の患者の使用バイオセンサーを含む。170万人以上の患者の研究は同社のNC-statの技術を使用され、ほぼ70万腓腹神経テストを含む630万神経テストが行われた。 ヌロメトリックスは、糖尿病の神経学的合併症の治療に焦点を当てた米国の医療企業。医療機器に加えて、患者用バイオ・センサ―または電極で構成される神経診断システムを開発・マ―ケットに従事する。製品は、｢Quell｣、｢SENSUS｣、｢DPNCheck｣、｢ADVANCE System｣などが有る。 NeuroMetrix is an innovation-driven company focused on the development and global commercialization of non-invasive medical devices for the diagnosis and treatment of disorders involving the nervous system. The Company has three commercial products. DPNCheck® is a diagnostic device that provides rapid, point-of-care detection of peripheral neuropathies. ADVANCE® is a diagnostic device that provides automated, in-office nerve conduction studies for the evaluation of focal neuropathies. Quell® is a wearable neurostimulation device indicated for symptomatic relief of chronic pain that is available over-the-counter. |
| 本社所在地 | 1000 Winter Street Waltham MA 02451 USA |
| 代表者氏名 | Shai N. Gozani シャイ・N・ゴザニ |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer Secretary |
| 電話番号 | +1 781-890-9989 |
| 設立年月日 | 35217 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2004年 |
| 従業員数 | － |
| url | www.neurometrix.com |
| nasdaq_url | https://www.nasdaq.com/symbol/nuro |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -12.90753 |
| 終値（lastsale） | 1.33 |
| 時価総額（marketcap） | 9784452.23 |
| 時価総額 | 時価総額（百万ドル） 9.34305 |
| 売上高 | 売上高（百万ドル） 17.17072 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 2.23415 |
| 当期純利益 | 当期純利益（百万ドル） -7.48197 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Neurometrix Inc revenues increased 1% to $8.7M. Net income applicable to common stockholders totaled $1.7M vs. loss of $10.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Sales and marketing decrease of 15% to $4.7M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$9.75 to $0.26. |
NUROのテクニカル分析
NUROのニュース
NeuroMetrix to Exhibit Quell Fibromyalgia and Present New Clinical Data at the American Academy of Pain Medicine 2023 Annual Meeting 2023/03/21 13:00:00 Wallstreet:Online
WOBURN, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) will exhibit Quell Fibromyalgia at the American Academy of Pain Medicine 39th Annual Meeting on March 23 - 26 in Ft. Lauderdale, FL. In addition, two scientific posters reporting new data on the use of Quell in patients with fibromyalgia will be presented. Fibromyalgia is a chronic condition characterized by generalized
NeuroMetrix, Inc. (NURO) Q4 2022 Earnings Call Transcript 2023/02/23 22:23:05 Seeking Alpha
NeuroMetrix, Inc. (NASDAQ:NASDAQ:NURO) Q4 2022 Results Conference Call February 23, 2023 8:00 AM ETCompany ParticipantsThomas Higgins - Senior VP, CFO & TreasurerShai Gozani - Founder,…
NeuroMetrix GAAP EPS of -$0.09, revenue of $1.84N 2023/02/23 12:16:30 Seeking Alpha
NeuroMetrix press release (NURO): Q4 GAAP EPS of -$0.09.Revenue of $1.84M (+1.1% Y/Y).Gross profit in Q4 2022 was $1.2 million, a decrease of 1.0% from the fourth quarter of 2021
NeuroMetrix Reports Q4 and Full Year 2022 Financial Results 2023/02/23 12:00:00 GlobeNewswire
WOBURN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2022. The Company''s mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on population health through innovative non-invasive medical devices.
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2022 Financial Results Conference Call 2023/02/16 19:58:00 GlobeNewswire
WOBURN, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 fourth quarter and year end financial results before the opening of the market on February 23, 2023. The Company will host a conference call at 8:00 a.m., Eastern Time on February 23, 2023 to discuss its financial results as well as business developments affecting the Company.
NeuroMetrix to Exhibit Quell Fibromyalgia and Present New Clinical Data at the American Academy of Pain Medicine 2023 Annual Meeting 2023/03/21 13:00:00 Wallstreet:Online
WOBURN, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) will exhibit Quell Fibromyalgia at the American Academy of Pain Medicine 39th Annual Meeting on March 23 - 26 in Ft. Lauderdale, FL. In addition, two scientific posters reporting new data on the use of Quell in patients with fibromyalgia will be presented. Fibromyalgia is a chronic condition characterized by generalized
NeuroMetrix, Inc. (NURO) Q4 2022 Earnings Call Transcript 2023/02/23 22:23:05 Seeking Alpha
NeuroMetrix, Inc. (NASDAQ:NASDAQ:NURO) Q4 2022 Results Conference Call February 23, 2023 8:00 AM ETCompany ParticipantsThomas Higgins - Senior VP, CFO & TreasurerShai Gozani - Founder,…
NeuroMetrix GAAP EPS of -$0.09, revenue of $1.84N 2023/02/23 12:16:30 Seeking Alpha
NeuroMetrix press release (NURO): Q4 GAAP EPS of -$0.09.Revenue of $1.84M (+1.1% Y/Y).Gross profit in Q4 2022 was $1.2 million, a decrease of 1.0% from the fourth quarter of 2021
NeuroMetrix Reports Q4 and Full Year 2022 Financial Results 2023/02/23 12:00:00 GlobeNewswire
WOBURN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2022. The Company''s mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on population health through innovative non-invasive medical devices.
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2022 Financial Results Conference Call 2023/02/16 19:58:00 GlobeNewswire
WOBURN, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 fourth quarter and year end financial results before the opening of the market on February 23, 2023. The Company will host a conference call at 8:00 a.m., Eastern Time on February 23, 2023 to discuss its financial results as well as business developments affecting the Company.
NeuroMetrix stock dips as Q2 net loss widens, revenue falls Y/Y 2022/07/21 15:16:43 Seeking Alpha
NeuroMetrix (NURO) stock fell ~3% after the company reported a decline in Q2 revenue and a widened net loss.Revenues fell -3.4% Y/Y to to $2.13M Y/Y
NeuroMetrix, Inc. (NURO) CEO Shai Gozani on Q2 2022 Results - Earnings Call Transcript 2022/07/21 15:14:15 Seeking Alpha
NeuroMetrix, Inc. (NASDAQ:NASDAQ:NURO) Q2 2022 Earnings Conference Call July 21, 2022 08:00 ET Company Participants Thomas Higgins - Senior Vice President and Chief Financial Officer Shai…
NeuroMetrix GAAP EPS of -$0.17, revenue of $2.1M 2022/07/21 11:07:18 Seeking Alpha
NeuroMetrix press release (NURO): Q2 GAAP EPS of -$0.17.Revenue of $2.1M (-5.0% Y/Y).
NeuroMetrix Reports Q2 2022 Financial Results 2022/07/21 11:00:00 GlobeNewswire
WOBURN, Mass., July 21, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and six months period ended June 30, 2022. The Company''s mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on population health through innovative non-invasive medical devices.
NeuroMetrix, Inc. Announces Date for Second Quarter 2022 Financial Results Conference Call 2022/07/14 15:32:00 GlobeNewswire
WOBURN, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 second quarter financial results before the opening of the market on July 21, 2022. The Company will host a conference call at 8:00 a.m., Eastern Time on July 21, 2022 to discuss its financial results as well as business developments affecting the Company.